Mark Daunis
Family Medicine · Hammond, LANPI 1215992813
Payments from drug & device makers
Across 217 payments — averaging $14.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$659
- Novo Nordisk$652
- GSK$447
- Amgen$422
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$257
- Lilly USA, LLC$166
- plus $514 from 12 others
What the payments were for
- Food & beverage$3,117100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $659 |
| Novo Nordisk | 47 | $652 |
| GSK | 30 | $447 |
| Amgen | 29 | $422 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $257 |
| Lilly USA, LLC | 12 | $166 |
| Esperion Therapeutics, Inc. | 7 | $107 |
| Johnson & Johnson | 7 | $101 |
| Amarin Pharma, Inc. | 3 | $65 |
| Tris Pharma Inc | 3 | $48 |
| Exact Sciences | 2 | $44 |
| Global Blood Therapeutics, Inc. | 2 | $33 |
| Pfizer | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Organon | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$3,117 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 70 | $61,128 |
| JanuviaSitagliptin Phosphate | 36 | $30,329 |
| EliquisApixaban | 29 | $22,145 |
| RayaldeeCalcifediol | 16 | $18,661 |
| OzempicSemaglutide | 15 | $14,335 |
| TrulicityDulaglutide | 14 | $13,135 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $12,885 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $12,650 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $10,436 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,373 |
| Repatha SureclickEvolocumab | 11 | $7,091 |
| TradjentaLinagliptin | 14 | $6,948 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $5,644 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,273 |
| VascepaIcosapent Ethyl | 15 | $5,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $14 | $68,07684 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $447 | $27,53146 claims |
| PfizerEliquis | $32 | $22,14529 claims |
| Novo NordiskOzempic | $652 | $14,33515 claims |
| Lilly USA, LLCTrulicity | $166 | $13,13514 claims |
| Esperion Therapeutics, Inc.Nexlizet | $107 | $10,43616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Hammond
- Leonard TreanorHammond$29K
- Claude GilbreathHammond$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.